Advertisement

Familial Cancer

, Volume 14, Issue 4, pp 545–551 | Cite as

Childhood cancers in families with and without Lynch syndrome

  • John A. Heath
  • Jeanette C. Reece
  • Daniel D. Buchanan
  • Graham Casey
  • Carol A. Durno
  • Steven Gallinger
  • Robert W. Haile
  • Polly A. Newcomb
  • John D. Potter
  • Stephen N. Thibodeau
  • Loïc Le Marchand
  • Noralane M. Lindor
  • John L. Hopper
  • Mark A. Jenkins
  • Aung Ko WinEmail author
Original Article

Abstract

Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes or the EPCAM gene is associated with an increased risk of colorectal cancer, endometrial cancer, and other adult malignancies (Lynch syndrome). The risk of childhood cancers in Lynch syndrome families, however, is not well studied. Using data from the Colon Cancer Family Registry, we compared the proportion of childhood cancers (diagnosed before 18 years of age) in the first-, second-, and third-degree relatives of 781 probands with a pathogenic mutation in one of the MMR genes; MLH1 (n = 275), MSH2 (n = 342), MSH6 (n = 99), or PMS2 (n = 55) or in EPCAM (n = 10) (Lynch syndrome families), with that of 5073 probands with MMR-deficient colorectal cancer (non-Lynch syndrome families). There was no evidence of a difference in the proportion of relatives with a childhood cancer between Lynch syndrome families (41/17,230; 0.24 %) and non-Lynch syndrome families (179/94,302; 0.19 %; p = 0.19). Incidence rate of all childhood cancers was estimated to be 147 (95 % CI 107–206) per million population per year in Lynch syndrome families and 115 (95 % CI 99.1–134) per million population per year in non-Lynch syndrome families. There was no evidence for a significant increase in the risk of all childhood cancers, hematologic cancers, brain and central nervous system cancers, Lynch syndrome-associated cancers, or other cancers in Lynch syndrome families compared with non-Lynch syndrome families. Larger studies, however, are required to more accurately define the risk of specific individual childhood cancers in Lynch syndrome families.

Keywords

Childhood cancer Familial cancer Lynch syndrome Mismatch repair 

Notes

Acknowledgments

The authors thank all study participants of the Colon Cancer Family Registry and staff for their contributions to this project. This work was supported by Grant UM1 CA167551 from the National Cancer Institute, National Institutes of Health and through cooperative agreements with members of the Colon Cancer Family Registry and Principal Investigators. Collaborating centers include Australasian Colorectal Cancer Family Registry (U01/U24 CA097735), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), Stanford Consortium Colorectal Cancer Family Registry (U01/U24 CA074799), and University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806). JAH is an Australian National Health and Medical Research Council (NHMRC) Career Development Fellow. MAJ is a NHMRC Senior Research Fellow. JLH is a NHMRC Senior Principal Research Fellow. AKW is an NHMRC Early Career Fellow. DDB is a University of Melbourne Research at Melbourne Accelerator Program (R@MAP) Senior Research Fellow.

Conflict of interest

The authors have no conflict of interest to declare with respect to this manuscript.

Supplementary material

10689_2015_9810_MOESM1_ESM.xlsx (13 kb)
Supplementary material 1 (XLSX 12 kb)

References

  1. 1.
    Jiricny J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7(5):335–346CrossRefPubMedGoogle Scholar
  2. 2.
    Lynch HT, Lynch J (2000) Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 18(1):19s–31sPubMedGoogle Scholar
  3. 3.
    Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41(1):112–117CrossRefPubMedGoogle Scholar
  4. 4.
    Umar A, Boland CR, Terdiman JP et al (2004) Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Win AK, Lindor N, Jenkins M (2013) Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res 15(2):R27PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Ryan S, Jenkins MA, Win AK (2014) Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(3):437–449CrossRefGoogle Scholar
  7. 7.
    Bakry D, Aronson M, Durno C et al (2014) Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 50(5):987–996CrossRefPubMedGoogle Scholar
  8. 8.
    Vasen HF, Ghorbanoghli Z, Bourdeaut F et al (2014) Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet 51(5):283–293CrossRefPubMedGoogle Scholar
  9. 9.
    Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomark Prev 16(11):2331–2343CrossRefGoogle Scholar
  10. 10.
    Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419–428PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Win AK, Lindor NM, Young JP et al (2012) Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst 104(18):1363–1372PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    StataCorp (2013) Stata statistical software: release 13. StataCorp LP, College StationGoogle Scholar
  13. 13.
    Howlader N, Noone A, Krapcho M et al (eds) (2014) SEER cancer statistics review, 1975–2011. National Cancer Institute, BethesdaGoogle Scholar
  14. 14.
    Baade PD, Youlden DR, Valery PC et al (2010) Population-based survival estimates for childhood cancer in Australia during the period 1997–2006. Br J Cancer 103(11):1663–1670PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Linabery AM, Ross JA (2008) Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer 112(2):416–432CrossRefPubMedGoogle Scholar
  16. 16.
    Stack M, Walsh PM, Comber H, Ryan CA, O’Lorcain P (2007) Childhood cancer in Ireland: a population-based study. Arch Dis Child 92(10):890–897PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Bao PP, Zheng Y, Wang CF, Gu K, Jin F, Lu W (2009) Time trends and characteristics of childhood cancer among children age 0–14 in Shanghai. Pediatr Blood Cancer 53(1):13–16CrossRefPubMedGoogle Scholar
  18. 18.
    Heath JA, Ng J, Beshay V, Coleman L, Lo P, Amor DJ (2013) Anaplastic oligodendroglioma in an adolescent with Lynch syndrome. Pediatr Blood Cancer 60(6):E13–E15CrossRefPubMedGoogle Scholar
  19. 19.
    Niessen RC, Berends MJ, Wu Y et al (2006) Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut 55(12):1781–1788PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Bodas A, Perez-Segura P, Maluenda C, Caldes T, Olivera E, Diaz-Rubio E (2008) Lynch syndrome in a 15-year-old boy. Eur J Pediatr 167(10):1213–1215CrossRefPubMedGoogle Scholar
  21. 21.
    Huang SC, Lavine JE, Boland PS et al (2001) Germline characterization of early-aged onset of hereditary non-polyposis colorectal cancer. J Pediatr 138(5):629–635CrossRefPubMedGoogle Scholar
  22. 22.
    Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H (2008) Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer 7(4):331–337CrossRefPubMedGoogle Scholar
  23. 23.
    Dunlop MG, Farrington SM, Nicholl I et al (2000) Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer 83(12):1643–1645PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Hampel H, de la Chapelle A (2011) The Search for unaffected individuals with Lynch syndrome: Do the ends justify the means? Cancer Prev Res 4(1):1–5CrossRefGoogle Scholar
  25. 25.
    Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014) Childhood and adolescent cancer statistics. CA Cancer J Clin 64(2):83–103CrossRefPubMedGoogle Scholar
  26. 26.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262CrossRefPubMedGoogle Scholar
  27. 27.
    Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • John A. Heath
    • 1
    • 2
  • Jeanette C. Reece
    • 1
  • Daniel D. Buchanan
    • 1
    • 3
  • Graham Casey
    • 4
  • Carol A. Durno
    • 5
    • 6
    • 7
  • Steven Gallinger
    • 8
  • Robert W. Haile
    • 9
  • Polly A. Newcomb
    • 10
    • 11
  • John D. Potter
    • 10
    • 11
    • 12
  • Stephen N. Thibodeau
    • 13
  • Loïc Le Marchand
    • 14
  • Noralane M. Lindor
    • 15
  • John L. Hopper
    • 1
    • 16
    • 17
  • Mark A. Jenkins
    • 1
  • Aung Ko Win
    • 1
    Email author
  1. 1.Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global HealthUniversity of MelbourneMelbourneAustralia
  2. 2.Department of OncologySidra Medical and Research CenterDohaQatar
  3. 3.Oncogenomics Group, Genetic Epidemiology Laboratory, Department of PathologyThe University of MelbourneParkvilleAustralia
  4. 4.Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  5. 5.Familial Gastrointestinal Cancer Registry, Zane Cohen Centre for Digestive DiseasesMount Sinai HospitalTorontoCanada
  6. 6.Department of Surgery, Mount Sinai HospitalTorontoCanada
  7. 7.Department of Paediatrics, Division of Gastroenterology, Hepatology and Nutrition, Hospital for Sick ChildrenUniversity of TorontoTorontoCanada
  8. 8.Lunenfeld Tanenbaum Research Institute, Mount Sinai HospitalUniversity of TorontoTorontoCanada
  9. 9.Division of Oncology, Department of MedicineStanford UniversityLos AngelesUSA
  10. 10.Public Health Sciences DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  11. 11.School of Public HealthUniversity of WashingtonSeattleUSA
  12. 12.Centre for Public Health ResearchMassey UniversityWellingtonNew Zealand
  13. 13.Molecular Genetics Laboratory, Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  14. 14.University of Hawaii Cancer CenterHonoluluUSA
  15. 15.Department of Health Science ResearchMayo Clinic ArizonaScottsdaleUSA
  16. 16.Department of Epidemiology, School of Public HealthSeoul National UniversitySeoulKorea
  17. 17.Institute of Health and EnvironmentSeoul National UniversitySeoulKorea

Personalised recommendations